IP Library › Granted Patent US 6,849,256
Granted Patent B1
US 6,849,256 · App. 09/708,870 · Granted Feb 1, 2005

Inhibition of pathogens by probiotic bacteria

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,849,256
App. No.
09/708,870
Granted
Feb 1, 2005
Kind
B1
Abstract

Composition containing a lactic acid-producing bacterial strain, e.g., Bacillus coagulans for inhibition of pathogenic bacterial infections. Spores or extracellular products produced by the bacterial strains are also useful as inhibitory agents.

Claims (10)

1. A method of inhibiting an infection, comprising administering to the gastrointestinal tract of an animal a composition comprising an isolated Bacillus strain, wherein said strain is selected from the group consisting of Bacillus coagulans GBI-20 (ATCC Designation Number PTA-6085), Bacillus coagulans GBI-30 (ATCC Designation Number PTA-6086) and Bacillus coagulans GBI-40 (ATCC Designation Number PTA-6087), or a combination thereof.

2. The method of claim 1 , wherein said composition comprises a viable vegetative bacterial cell.

3. The method of claim 1 , wherein said composition comprises a bacterial spore.

4. The method of claim 2 , wherein said composition is administered at a dose of 1×10 2 to 1×10 14 viable vegetative bacterial cells per day.

5. The method of claim 3 , wherein said composition is administered at a dose of 1×10 2 to 1×10 14 spores per day.

6. The method of claim 1 , wherein said composition is administered orally or buccally.

7. A method of inhibiting an infection, comprising administering to the gastrointestinal tract of an animal a composition comprising isolated Bacillus coagulans GBI-20 (ATCC Designation Number PTA-6085).

8. A method of inhibiting an infection, comprising administering to the gastrointestinal tract of an animal a composition comprising isolated Bacillus coagulans GBI-30 (ATCC Designation Number PTA-6086).

9. A method of inhibiting an infection, comprising administering to the gastrointestinal tract of an animal a composition comprising isolated Bacillus coagulans GBI-40 (ATCC Designation Number PTA-6087).

10. A method of inhibiting an infection, comprising administering to the gastrointestinal tract of an animal a composition comprising isolated Bacillus coagulans GBI-20 (ATCC Designation Number PTA-6085), isolated Bacillus coagulans GBI-30 (ATCC Designation Number PTA-6086), and isolated Bacillus coagulans GBI-40 (ATCC Designation Number PTA-6087).

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Sep 12, 2017
From: SILICON VALLEY BANK
To: GANEDEN BIOTECH, INC.
Reel/Frame 043822/0897 →
SECURITY AGREEMENT Recorded Oct 10, 2012
From: GANEDEN BIOTECH, INC.
To: SILICON VALLEY BANK
Reel/Frame 029103/0069 →
LICENSE Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0128 →
SECURITY AGREEMENT Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0950 →
RELEASE OF SECURITY INTEREST Recorded Dec 6, 2007
From: MIDCAP CREDIT, LLC
To: GANEDEN BIOTECH, INC.
Reel/Frame 020196/0851 →
SECURITY INTEREST Recorded Dec 23, 2005
From: GANEDEN BIOTECH, INC.
To: MIDCAP CREDIT, LLC
Reel/Frame 017136/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2003
From: FARMER, SEAN
To: GANEDEN BIOTECH, INCORPORATED
Reel/Frame 014114/0235 →